SEC Company Response from Clearside Biomedical, Inc. (CLSD) (CIK 0001539029) (CLSDQ) — Jan 15, 2020
Clearside Biomedical, Inc. (CLSD) (CIK 0001539029)
Date: Jan. 15, 2020 · CIK: 0001539029 · Accession: 0001564590-20-001172
AI Filing Summary & Sentiment
File numbers found in text: 333-235880
Letter
clsd-corresp.htm
January 15, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn:Tim Buchmiller
Re:Clearside Biomedical, Inc.
Registration Statement on Form S-3
Filed January 10, 2020
File No. 333-235880
Acceleration Request
Requested Date:January 17, 2020
Requested Time:4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-235880) (the “Registration Statement”) to become effective on January 17, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP, counsel to the Registrant, confirming this request. The Registrant hereby authorizes each of Brent Siler, Brian Leaf, Mark Ballantyne and Asheley Walker of Cooley LLP to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Brent Siler of Cooley LLP, counsel to the Registrant, at (202) 728-7040, or in his absence, either of Brian Leaf of Cooley LLP, counsel to the Registrant, at (703) 456-8053 or Mark Ballantyne at (703) 456-8084.
[Signature page follows]
Very truly yours,
Clearside Biomedical, Inc.
Show Raw Text
CORRESP 1 filename1.htm clsd-corresp.htm January 15, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn:Tim Buchmiller Re:Clearside Biomedical, Inc. Registration Statement on Form S-3 Filed January 10, 2020 File No. 333-235880 Acceleration Request Requested Date:January 17, 2020 Requested Time:4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-235880) (the “Registration Statement”) to become effective on January 17, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from Cooley LLP, counsel to the Registrant, confirming this request. The Registrant hereby authorizes each of Brent Siler, Brian Leaf, Mark Ballantyne and Asheley Walker of Cooley LLP to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brent Siler of Cooley LLP, counsel to the Registrant, at (202) 728-7040, or in his absence, either of Brian Leaf of Cooley LLP, counsel to the Registrant, at (703) 456-8053 or Mark Ballantyne at (703) 456-8084. [Signature page follows] Very truly yours, Clearside Biomedical, Inc. By: /s/ Charles A. Deignan Charles A. Deignan Chief Financial Officer cc:George Lasezkay, Clearside Biomedical, Inc. Brent B. Siler, Cooley LLP Brian F. Leaf, Cooley LLP Mark Ballantyne, Cooley LLP